New immune cell therapy tested for Tough-to-Treat cancers
NCT ID NCT06556108
Summary
This small, early-stage study tested a new type of personalized immune cell therapy called ALPP CAR-T in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to see if the treatment was safe and if it could shrink tumors. Researchers collected and modified a patient's own immune cells to target a specific protein found on their cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Hematology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.